CONTROL4LIFE: Continence, Sexual Function, Fitness and the Health of Men After Surgery for Prostate Cancer

Sponsor
University of Alberta (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06072911
Collaborator
(none)
106
1
2
29.5
3.6

Study Details

Study Description

Brief Summary

The Continence, Sexual and Metabolic Health (CONTROL 4 LIFE) study will evaluate the recovery of continence, sexual function, and health outcomes in individuals who have undergone surgery for prostate cancer. The purpose of this study is to better understand the timelines of recovery for these outcomes after surgery for prostate cancer. As part of this study, all participants will receive resources offered by Alberta Health Services regarding pre- and post-prostatectomy care, including information on pelvic floor exercises. Through the CONTROL 4 LIFE study, the investigators will also be evaluating outcomes related to physical activity, fitness and quality of life. These assessments will enable the investigators to better understand how well and how long it takes for individuals to recover after surgery for prostate cancer.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Pelvic floor exercise program
  • Behavioral: General exercise
  • Behavioral: Physical Activity Counseling
N/A

Detailed Description

The investigators aim to conduct a trial examining the feasibility and the effects of a combined pelvic health rehabilitation and exercise program that can be delivered both in-person and virtually in individuals who have been treated with prostatectomy for prostate cancer. This hybrid format will support equitable program delivery regardless of location of residence. To address issues faced by men with prostate cancer, the investigators propose an intervention (offered virtually and in-person) that includes: 1) online education to support continence, sexual and overall health; 2) a group exercise fitness program that considers the needs and restrictions specific to the early post-prostatectomy surgical period, and 3) functional and intensive pelvic floor muscle exercise retraining to promote continence and sexual recovery.

Main objectives of this study

  1. Determine the feasibility, defined as the acceptability and appropriateness, of a combined pelvic health rehabilitation and exercise fitness program that can be delivered both in-person and virtually.

  2. Determine the effects of the program on the primary outcome measure of urinary continence in comparison with usual care.

Secondary objectives of this study

  1. To determine the effects of the program on cardiometabolic indicators in comparison with usual care.

  2. To determine the effects of the program on general fitness, secondary outcomes of urinary continence, sexual function, self-efficacy, and cancer symptom burden, in comparison with usual care.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
106 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Zelen design with randomizationZelen design with randomization
Masking:
Double (Participant, Outcomes Assessor)
Masking Description:
The participants will be randomized after the baseline assessment and will have the option to take part in an additional exercise intervention component.
Primary Purpose:
Supportive Care
Official Title:
Continence, Sexual and Metabolic Health Programming to Promote Prostate Cancer Wellness for Life (CONTROL4LIFE)
Anticipated Study Start Date :
Jan 15, 2024
Anticipated Primary Completion Date :
Dec 31, 2025
Anticipated Study Completion Date :
Jun 30, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention

Pelvic floor exercise program and general exercise programming

Behavioral: Pelvic floor exercise program
General exercises will be prescribed along with a specialized pelvic floor program

Behavioral: General exercise
A general progressive resistance exercise program

Active Comparator: Control

Pelvic floor exercises and standard care (physical activity counseling)

Behavioral: Pelvic floor exercise program
General exercises will be prescribed along with a specialized pelvic floor program

Behavioral: Physical Activity Counseling
Advice on increasing physical activity

Outcome Measures

Primary Outcome Measures

  1. Completion Rate [Final assessment at one year]

    The number of participants completing the study including all planned outcomes

Secondary Outcome Measures

  1. Recruitment rate [One year]

    Percentage of participants who are eligible and agree to participate

  2. Adherence rate [Post-intervention: 12 weeks]

    Adherence to the intervention components

  3. 24-hour pad test [24 hours at two time points: immediate post surgery and 12 weeks]

    Mean: Individual's urine loss by measuring weight (grams) of an absorbent pad

  4. Expanded Prostate Cancer Index Composite for Clinical Practice [One-year]

    16-questions: urinary function, sexual and erectile function, bowel and hormonal function; Scores: 0 (no symptoms) to 60 (most severe symptoms); Higher scores indicate worse functioning

  5. International Consultation on Incontinence Questionnaire [One-year]

    13 questions: occurrence and bother of lower urinary tract symptoms, quality of life; Range of scores: 0-20 voiding subscale; 0-20 incontinence symptoms; Higher scores indicate worse functioning

  6. 36-Item Short Form Survey [One-year]

    Quality of life measure: Items are scored 0-100 (percentage of total possible score): Higher scores equal better quality of life

  7. Edmonton Symptom Assessment Scale [One year]

    11-item ordinal scale; Range 0-60; with higher scores indicating higher symptom burden

  8. Self-efficacy Questionnaire: Incontinence [One year]

    6 item ordinal scale: Range 0-60; Higher scores indicating higher self-efficacy

  9. Grip Strength [12 weeks]

    Dyanometer: mean in kgs

  10. Lower body strength [12-weeks]

    Sit-to-stand: mean number completed in 30 seconds

  11. Upper limb mobility [12 weeks]

    Shoulder Range of Motion: mean value in degrees

  12. Flexibility [12-weeks]

    Sit and reach: mean value in cm

  13. Balance [12-weeks]

    One-leg stance test: mean time in seconds

  14. Walking endurance [12-weeks]

    Six-minute walk test: mean distance in metres

  15. Body Mass Index [12-weeks]

    Height and weight will be combined to calculate BMI: mean: weight in kilograms divided by height in metres squared

  16. Glucose [12-weeks]

    mmol/L (mean value)

  17. Insulin level [12-weeks]

    mmol/L (mean value)

  18. Lipid profile [12-weeks]

    Cholesterol level: mg/dL (mean value)

  19. Hemoglobin A1c [12-weeks]

    Value in percentage (mean value)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • have a diagnosis of prostate cancer (stage I to IV);

  • be scheduled for a prostatectomy surgery (any surgical approach);

  • have no restriction to participate in at least mild levels of physical activity, as confirmed by the Physical Activity Readiness Questionnaire (PAR-Q+);

  • speak and understand English.

  • adult: 18 years of age or older

  • optional exercise component: willing and able to commit to the 12-week intervention

Exclusion Criteria:
  • have any medical conditions that may interfere with continence (i.e. neurological diseases);

  • have any contraindications to exercise testing or training;

  • have recent (>6 months) modifications to any medication aiming to reduce urinary incontinence (i.e. Myrbetric);

  • do not have regular access to the internet and a smart device or a computer at home/ at their community center;

  • are already receiving a pelvic floor exercise program through a pelvic floor physical therapist from their community.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Alberta Edmonton Alberta Canada T6G 2G4

Sponsors and Collaborators

  • University of Alberta

Investigators

  • Principal Investigator: Nathan Hoy, MD, University of Alberta
  • Principal Investigator: Howard Evans, MD, University of Alberta
  • Principal Investigator: Margaret McNeely, University of Alberta

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Margie McNeely, Professor, University of Alberta
ClinicalTrials.gov Identifier:
NCT06072911
Other Study ID Numbers:
  • HREBA.CC-23-0207
First Posted:
Oct 10, 2023
Last Update Posted:
Oct 13, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 13, 2023